IBD&me: Optimizing Selection of Biologic and Small Molecule Therapies in IBD
Cedars Sinai Medical Center
Biologics remain the mainstay of treatment for those with moderate-to-severe inflammatory bowel disease (IBD). However, drug development in IBD is dynamic; many additional therapies with novel mechanisms of action are in the pipeline. For example, a novel oral Janus kinase inhibitor called tofacitinib was recently shown to be efficacious in ulcerative colitis.
Currently, there are multiple first-line IBD therapies, and it can be difficult for patients to navigate the array of treatment options. Moreover, the decision-making process will become even more complex as additional effective therapies are developed, tested, and approved for use in clinical practice. To facilitate shared decision-making (SDM) focused on IBD treatments, our research group created IBD&me (ibdandme.org) – a free, online, unbranded resource that offers an immersive and interactive decision aid that supports patients in selecting a treatment that is congruent with their preferences and beliefs. IBD&me also uses conjoint analysis to generate a unique personalized report designed to help doctors efficiently and effectively understand their patients' treatment preferences.
As part of this study, we aim to assess the impact of IBD&me on patient perceptions of SDM and satisfaction when compared to a standardized education arm in a multicenter randomized controlled trial in partnership with IBD Qorus. Moreover, in a separate aim, we will assess how IBD patients navigate and make decisions when selecting among current and emerging IBD therapies (i.e., small molecules) using conjoint analysis; these results will inform future updates to the IBD&me decision tool as new therapies are approved for use in clinical practice.
|Full Proposal||Interim Reports||Final Report|
Improving Patient Care in IBD